Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Entwisle

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Cancer Gene Therapy|October 7, 2000
Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancerS H Kim, J F Carew, D A Kooby, et al.
The Journal of General Virology|February 27, 2003
Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virusM Lucas, E Tsitoura, M Montoya, et al.
The Journal of Biological Chemistry|February 5, 1988
A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domainM J Browne, J E Carey, C G Chapman, et al.
Circulation|August 1, 1992
A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activatorJ H Robinson, M J Browne, J E Carey, et al.
The Journal of Infectious Diseases|January 1, 1997
A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 diseaseM E Boursnell, C Entwisle, D Blakeley, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancerM E Boursnell, C Entwisle, S A Ali, et al.
Cancer Research|April 5, 2000
Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genesS A Ali, C S McLean, M E Boursnell, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Cancer Gene Therapy|October 7, 2000
Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancerS H Kim, J F Carew, D A Kooby, et al.
The Journal of General Virology|February 27, 2003
Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virusM Lucas, E Tsitoura, M Montoya, et al.
The Journal of Biological Chemistry|February 5, 1988
A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domainM J Browne, J E Carey, C G Chapman, et al.
Circulation|August 1, 1992
A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activatorJ H Robinson, M J Browne, J E Carey, et al.
The Journal of Infectious Diseases|January 1, 1997
A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 diseaseM E Boursnell, C Entwisle, D Blakeley, et al.
Advances in Experimental Medicine and Biology|February 23, 1999
Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancerM E Boursnell, C Entwisle, S A Ali, et al.
Cancer Research|April 5, 2000
Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genesS A Ali, C S McLean, M E Boursnell, et al.
Pageof 2